Cardiovascular nanomedicine: Challenges and opportunities

Molecular and Translational Vascular Medicine

Volumn , Issue , 2012, Pages 249-281

  Godin, Biana ^a   Hu, Ye ^a   La Francesca, Saverio ^b   Ferrari, Mauro ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903657378     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-906-8_9     Document Type: Chapter

References (152)

1. Godin B, Driessen WH, Proneth B, et al. An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet. 2010;69:31-64.
2. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine- challenge and perspectives. Angew Chem Int Ed Engl. 2009;48(5):872-97.
3. Theis T, Parr D, Binks P, et al. Nan'o.tech.nol'o.gy n. Nat Nanotechnol. 2006;1(1):8-10.
4. Godin B, Serda RE, Sakamoto J, Decuzzi P, Ferrari M. Nanoparticles for cancer detection and therapy. In: Vogel V editor. Nanotechnology. Volume 5: Nanomedicine and Nano biotechnology, Wiley-VCH Verlag GmbH&Co. Germany: KGaA Weinheirn; 2009. p. 51-88.
5. Sanhai WR, Sakamoto JH, Canady R, Ferrari M. Seven challenges for nanomedicine. Nat Nanotechnol. 2008;3(5):242-4.
6. Buxton DB, Lee SC, Wickline SA, Ferrari M. Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation. 2003;108(22):2737-42.
7. Lee CC, MacKay JA, Frechet JM, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol. 2005;23(12):1517-26.
8. Sun G, Berezin MY, Fan J, et al. Bright fl uorescent nanoparticles for developing potential optical imaging contrast agents. Nanoscale. 2010;2(4):548-58.
9. Amir RJ, Albertazzi L, Willis J, Khan A, Kang T, Hawker CJ. Multifunctional trackable dendritic scaffolds and delivery agents. Angew Chem Int Ed Engl. 2011;50(15):3425-9.
10. Chan JM, Zhang L, Tong R, et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A. 2010;107(5):2213-8.
11. Radisic M, Park H, Gerecht S, Cannizzaro C, Langer R, Vunjak-Novakovic G. Biomimetic approach to cardiac tissue engineering. Philos Trans R Soc Lond B Biol Sci. 2007;362(1484): 1357-68.
12. Zhao W, Schafer S, Choi J, et al. Cell-surface sensors for real-time probing of cellular environments. Nat Nanotechnol. 2011;6:524-31.
13. Winau F, Westphal O, Winau R. Paul Ehrlich-in search of the magic bullet. Microbes Infect. 2004;6(8):786-9.
14. Blagosklonny MV. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle. 2004;3(8):1035-42.
15. HatefiA, Amsden B. Camptothecin delivery methods. Pharm Res. 2002;19(10):1389-99.
16. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007;24(6):1029-46.
17. Huuskonen J, Salo M, Taskinen J. Neural network modeling for estimation of the aqueous solubility of structurally related drugs. J Pharm Sci. 1997;86(4):450-4.
18. Ferrari M. Nanovector therapeutics. Curr Opin Chem Biol. 2005;9(4):343-6.
19. Canal P, Gamelin E, Vassal G, Robert J. Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy. Pathol Oncol Res. 1998;4(3):171-8.
20. Tallaj JA, Franco V, Rayburn BK, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24(12): 2196-201.
21. Heath JR, Davis ME. Nanotechnology and cancer. Annu Rev Med. 2008;59:251-65.
22. Wang MD, Shin DM, Simons JW, Nie S. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther. 2007;7(6):833-7.
23. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24(10):1211-7.
24. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3): 161-71.
25. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-60.
26. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156(4):1363-80.
27. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41: 189-207.
28. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214-21.
29. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71(3):409-19.
30. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6(9): 688-701.
31. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5): 347-60.
32. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649-59.
33. Kale AA, Torchilin VP. "Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes. J Liposome Res. 2007;17(3-4):197-203.
34. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.
35. Souza GR, Staquicini FI, Christianson DR, et al. Combinatorial targeting and nanotechnology applications. Biomed Microdev. 2010;12:597-606.
36. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52(19): 5144-53.
37. Levchenko TS, Hartner WC, Verma DD, Bernstein EA, Torchilin VP. ATP-loaded liposomes for targeted treatment in models of myocardial ischemia. Methods Mol Biol. 2010;605: 361-75.
38. Mikhaylov G, Mikac U, Magaeva AA, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol. 2011;6(9): 594-602.
39. Ferrari M. Frontiers in cancer nanomedicine: transport oncophysics and logic-embedded vectors. Trends Biotechnol. 2010;28:181-8.
40. Serda RE, Mack A, van de Ven AL, et al. Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small. 2010;6(23):2691-700.
41. Mitragotri S. In drug delivery, shape does matter. Pharm Res. 2009;26(1):232-4.
42. Chiappini C, Tasciotti E, Fakhoury JR, et al. Tailored porous silicon microparticles: fabrication and properties. Chemphyschem. 2010;11(5):1029-35.
43. Ananta JS, Godin B, Sethi R, et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol. 2010;5(11):815-21.
44. Decuzzi P, Ferrari M. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials. 2007;28(18):2915-22.
45. Decuzzi P, Ferrari M. Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials. 2008;29(3):377-84.
46. Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2010;141(3):320-7.
47. Decuzzi P, Lee S, Decuzzi M, Ferrari M. Adhesion of microfabricated particles on vascular endothelium: a parametric analysis. Ann Biomed Eng. 2004;32:793-802.
48. Lee SY, Ferrari M, Decuzzi P. Shaping nano-/micro-particles for enhanced vascular interaction in laminar fl ows. Nanotechnology. 2009;20(49):495101.
49. Lee SY, Ferrari M, Decuzzi P. Design of bio-mimetic particles with enhanced vascular interaction. J Biomech. 2009;42(12):1885-90.
50. Serda RE, Ferrati S, Godin B, Tasciotti E, Liu X, Ferrari M. Mitotic partitioning of silicon microparticles. Nanoscale. 2009;1(2):250-9.
51. Serda RE, Gu J, Bhavane RC, et al. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials. 2009;30(13):2440-8.
52. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A. 2006;103(13):4930-4.
53. Muro S, Garnacho C, Champion JA, et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther. 2008;16(8):1450-8.
54. Doshi N, Mitragotri S. Needle-shaped polymeric particles induce transient disruption of cell membranes. J R Soc Interface. 2010;7 Suppl 4:S403-10.
55. Ferrari M. Nanogeometry: beyond drug delivery. Nat Nanotechnol. 2008;3(3):131-2.
56. Ferrati S, Mack A, Chiappini C, et al. Intracellular trafficking of silicon particles and logicembedded vectors. Nanoscale. 2010.
57. Zimmerberg J, Kozlov MM. How proteins produce cellular membrane curvature. Nat Rev Mol Cell Biol. 2006;7(1):9-19.
58. Reynwar BJ, Illya G, Harmandaris VA, Muller MM, Kremer K, Deserno M. Aggregation and vesiculation of membrane proteins by curvature-mediated interactions. Nature. 2007; 447(7143):461-4.
59. Koval M, Preiter K, Adles C, Stahl PD, Steinberg TH. Size of IgG-opsonized particles determines macrophage response during internalization. Exp Cell Res. 1998;242(1):265-73.
60. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004;377(Pt 1): 159-69.
61. Jin H, Heller DA, Sharma R, Strano MS. Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. ACS Nano. 2009;3(1):149-58.
62. Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv. 2010; 7(4):479-95.
63. Yoo JW, Mitragotri S. Polymer particles that switch shape in response to a stimulus. Proc Natl Acad Sci U S A. 2010;107(25):11205-10.
64. Decuzzi P, Ferrari M. The receptor-mediated endocytosis of nonspherical particles. Biophys J. 2008;94(10):3790-7.
65. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
66. Danenberg HD, Fishbein I, Gao J, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation. 2002;106(5):599-605.
67. Stephan D, Gasser B, San H, Schubnel M, Nabel GJ, Nabel EG. Direct gene transfer in the rat kidney in vivo. Arch Mal Coeur Vaiss. 1997;90(8):1127-30.
68. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation. 2003;107(21):2677-83.
69. Lanza GM, Winter PM, Caruthers SD, et al. Nanomedicine opportunities for cardiovascular disease with per fl uorocarbon nanoparticles. Nanomedicine. 2006;1(3):321-9.
70. Jaffer FA, Libby P, Weissleder R. Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(7):1017-24.
71. Yin X, Fu Y, Yutani C, Ikeda Y, Enjyoji K, Kato H. HVJ-AVE liposome-mediated tissue factor pathway inhibitor (TFPI) gene transfer with recombinant TFPI (rTFPI) irrigation attenuates restenosis in atherosclerotic arteries. Int J Cardiol. 2009;135(2):245-8.
72. Lanza GM, Winter PM, Caruthers SD, et al. Theragnostics for tumor and plaque angiogenesis with per fl uorocarbon nanoemulsions. Angiogenesis. 2010;13(2):189-202.
73. Fishbein I, Waltenberger J, Banai S, et al. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol. 2000;20(3):667-76.
74. Banai S, Chorny M, Gertz SD, et al. Locally delivered nanoencapsulated tyrphostin (AGL- 2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials. 2005;26(4):451-61.
75. Godin B, Sakamoto JH, Serda RE, Grattoni A, Bouamrani A, Ferrari M. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci. 2010;31(5):199-205.
76. Heroux J, Gharib AM, Danthi NS, Cecchini S, Ohayon J, Pettigrew RI. High-affinity alphavbeta3 integrin targeted optical probe as a new imaging biomarker for early atherosclerosis: initial studies in Watanabe rabbits. Mol Imaging Biol. 2010;12(1):2-8.
77. Bielinski SJ, Pankow JS, Li N, et al. ICAM1 and VCAM1 polymorphisms, coronary artery calcium, and circulating levels of soluble ICAM-1: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2008;201(2):339-44.
78. Jun HW, West J. Development of a YIGSR-peptide-modified polyurethaneurea to enhance endothelialization. J Biomater Sci Polym Ed. 2004;15(1):73-94.
79. Li JM, Newburger PE, Gounis MJ, Dargon P, Zhang X, Messina LM. Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model. Gene Ther. 2010;17(10):1279-87.
80. Gu Z, Rolfe BE, Xu ZP, Thomas AC, Campbell JH, Lu GQ. Enhanced effects of low molecular weight heparin intercalated with layered double hydroxide nanoparticles on rat vascular smooth muscle cells. Biomaterials. 2010;31(20):5455-62.
81. Reddy MK, Vasir JK, Sahoo SK, Jain TK, Yallapu MM, Labhasetwar V. Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circ Cardiovasc Interv. 2008;1(3):209-16.
82. Fishbein I, Chorny M, Banai S, et al. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol. 2001;21(9):1434-9.
83. Calin MV, Manduteanu I, Dragomir E, et al. Effect of depletion of monocytes/macrophages on early aortic valve lesion in experimental hyperlipidemia. Cell Tissue Res. 2009;336(2): 237-48.
84. Luderer F, Lobler M, Rohm HW, et al. Biodegradable sirolimus-loaded poly(lactide) nanoparticles as drug delivery system for the prevention of in-stent restenosis in coronary stent application. J Biomater Appl. 2011;25(8):851-75.
85. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging. 2008;1(5):624-34.
86. Hartner WC, Verma DD, Levchenko TS, Bernstein EA, Torchilin VP. ATP-loaded liposomes for treatment of myocardial ischemia. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(5):530-9.
87. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006;58(14):1471-504.
88. Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman Jr JR. Advanced multiplexed analysis with the FlowMetrixTM system. Clin Chem. 1997;43(9):1749-56.
89. Cheung VG, Morley M, Aguilar F, Massimi A, Kucherlapati R, Childs G. Making and reading microarrays. Nat Genet. 1999;21:15-9.
90. Lockhart DJ, Dong H, Byrne MC, et al. Expression monitoring by hybridization to highdensity oligonucleotide arrays. Nat Biotechnol. 1996;14(13):1675-80.
91. Chen BPC, Li Y-S, Zhao Y, et al. DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol Genomics. 2001;7(1):55-63.
92. Ni C-W, Qiu H, Rezvan A, et al. Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed fl ow. Blood. 2010;116(15):e66-73.
93. Hamik A, Jain MK. Shear stress: devil's in the details. Blood. 2010;116(15):2625-6.
94. Kruse JJ, te Poele JA, Russell NS, Boersma LJ, Stewart FA. Microarray analysis to identify molecular mechanisms of radiation-induced microvascular damage in normal tissues. Int J Radiat Oncol Biol Phys. 2004;58(2):420-6.
95. Nam J-M, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science. 2003;301(5641):1884-6.
96. Thaxton CS, Hill HD, Georganopoulou DG, Stoeva SI, Mirkin CA. A bio-bar-code assay based upon dithiothreitol-induced oligonucleotide release. Anal Chem. 2005;77(24):8174-8.
97. Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature. 1996;382(6592):607-9.
98. Elghanian R, Storhoff JJ, Mucic RC, Letsinger RL, Mirkin CA. Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science. 1997;277(5329):1078-81.
99. Georganopoulou DG, Chang L, Nam J-M, et al. Nanoparticle-based detection in cerebral spinal fl uid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A. 2005;102(7):2273-6.
100. Milewicz DM, Seidman CE. Genetics of cardiovascular disease. Circulation. 2000;102 Suppl 4:IV-103-11.
101. Dabek J, Owczarek A, Gasior Z, et al. Oligonucleotide microarray analysis of genes regulating apoptosis in chronically ischemic and postinfarction myocardium. Biochem Genet. 2008;46(5-6):241-7.
102. Dorn GW, Matkovich SJ. Put your chips on transcriptomics. Circulation. 2008;118(3): 216-8.
103. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311(13):819-23.
104. Heidecker B, Kasper EK, Wittstein IS, et al. Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. Circulation. 2008;118(3):238-46.
105. Goluch ED, Nam J-M, Georganopoulou DG, et al. A bio-barcode assay for on-chip attomolar- sensitivity protein detection. Lab Chip. 2006;6(10):1293-9.
106. Kao CY, Hoffman EA, Beck KC, Bellamkonda RV, Annapragada AV. Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad Radiol. 2003; 10(5):475-83.
107. Mukundan Jr S, Ghaghada KB, Badea CT, et al. A liposomal nanoscale contrast agent for preclinical CT in mice. AJR Am J Roentgenol. 2006;186(2):300-7.
108. Pan D, Williams TA, Senpan A, et al. Detecting vascular biosignatures with a colloidal, radioopaque polymeric nanoparticle. J Am Chem Soc. 2009;131(42):15522-7.
109. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103(3):415-22.
110. Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther. 2005; 3(4):705-15.
111. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60(11):1252-65.
112. Schoenhagen P, Conyers JL. Nanotechnology and atherosclerosis imaging: emerging diagnostic and therapeutic applications. Recent Pat Cardiovasc Drug Discov. 2008;3(2):98-104.
113. Cunningham CH, Arai T, Yang PC, McConnell MV, Pauly JM, Conolly SM. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med. 2005;53(5):999-1005.
114. Pan D, Senpan A, Caruthers SD, et al. Sensitive and efficient detection of thrombus withfibrin-specific manganese nanocolloids. Chem Commun. 2009;22:3234-6.
115. Pan D, Caruthers SD, Hu G, et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc. 2008;130(29):9186-7.
116. Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A. 2007;104(3):961-6.
117. Botnar RM, Buecker A, Wiethoff AJ, et al. In vivo magnetic resonance imaging of coronary thrombosis using afibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004;110(11):1463-6.
118. Cyrus T, Abendschein DR, Caruthers SD, et al. MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson. 2006; 8(3):535-41.
119. Morawski AM, Winter PM, Crowder KC, et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med. 2004;51(3):480-6.
120. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in earlystage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003;108(18):2270-4.
121. Chen W, Vucic E, Leupold E, et al. Incorporation of an apoE-derived lipopeptide in highdensity lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging. 2008;3(6):233-42.
122. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies in fl ammatory activation of cells in atherosclerosis. Circulation. 2006; 114(14):1504-11.
123. Wickline SA, Lanza GM. Molecular imaging, targeted therapeutics, and nanoscience. J Cell Biochem. 2002;87(S39):90-7.
124. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in in fl ammatory atherosclerosis. Circulation. 2008;117(3):379-87.
125. Anderson CJ, Dehdashti F, Cutler PD, et al. 64Cu-TETA-octreotide as a pet imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42(2):213-21.
126. Devaraj NK, Keliher EJ, Thurber GM, Nahrendorf M, Weissleder R. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem. 2009;20(2):397-401.
127. Mulder WJM, Koole R, Brandwijk RJ, et al. Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett. 2005;6(1):1-6.
128. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344(15):1117-24.
129. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331(8):496-501.
130. Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian metaanalysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364(9434): 583-91.
131. Liu D-M, Yang Q, Troczynski T. Sol-gel hydroxyapatite coatings on stainless steel substrates. Biomaterials. 2002;23(3):691-8.
132. Areva S, Paldan H, Peltola T, Närhi T, Jokinen M, Lindén M. Use of sol-gel-derived titania coating for direct soft tissue attachment. J Biomed Mater Res A. 2004;70A(2):169-78.
133. Gultepe E, Nagesha D, Sridhar S, Amiji M. Nanoporous inorganic membranes or coatings for sustained drug delivery in implantable devices. Adv Drug Deliv Rev. 2010;62(3):305-15.
134. Gultepe E, Nagesha D, Casse BDF, et al. Sustained drug release from non-eroding nanoporous templates. Small. 2010;6(2):213-6.
135. Meng J, Kong H, Xu HY, Song L, Wang CY, Xie SS. Improving the blood compatibility of polyurethane using carbon nanotubes asfillers and its implications to cardiovascular surgery. J Biomed Mater Res A. 2005;74A(2):208-14.
136. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335-62.
137. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of in fl ammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350(14):1387-97.
138. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655-63.
139. Danesh J, Lewington S, Thompson SG, et al. Plasmafibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799-809.
140. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19(3):493-8.
141. Mangoni AA, Jackson SH. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med. 2002;112(7):556-65.
142. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction offirst major cardiovascular events and death. N Engl J Med. 2006;355(25):2631-9.
143. Gaspari M, Ming-Cheng Cheng M, Terracciano R, et al. Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. J Proteome Res. 2006;5(5):1261-6.
144. Luchini A, Geho DH, Bishop B, et al. Smart hydrogel particles: biomarker harvesting: onestep affinity purification, size exclusion, and protection against degradation. Nano Lett. 2008;8(1):350-61.
145. McMurray AA, Ali Z, Kyselovik J, et al. A novel point of care diagnostic device: impedimetric detection of a biomarker in whole blood. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:115-8.
146. Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation. 2000;102(11):1216-20.
147. Wilson SR, Sabatine MS, Braunwald E, Sloan S, Murphy SA, Morrow DA. Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 trial. Am Heart J. 2009;158(3):386-91.
148. Park JS, Cho MK, Lee EJ, et al. A highly sensitive and selective diagnostic assay based on virus nanoparticles. Nat Nanotechnol. 2009;4(4):259-64.
149. Januzzi JL, Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation. 2010;121(10): 1227-34.
150. Mulder WJM, Cormode DP, Hak S, Lobatto ME, Silvera S, Fayad ZA. Multimodality nanotracers for cardiovascular applications. Nat Clin Pract Cardiovasc Med. 2008;5:S103-11.
151. Chang TMS. Blood replacement with nanobiotechnologically engineered hemoglobin and hemoglobin nanocapsules. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(4): 418-30.
152. Freitas RJ. Current status of nanomedicine and medical nanorobotics. J Comput Theor Nanosci. 2005;2:1-25.